Trial reportScientific reports2026
Tear biomarker changes and ocular surface recovery with low-level light therapy after cataract surgery: a double-masked randomized controlled clinical trial.
Trial report in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Dry eye disease (DED) is a common complication following cataract-surgery, potentially impairing visual recovery. Low-level light therapy (LLLT) has emerged as a noninvasive approach to improve ocular surface status. This study evaluated the perioperative effects of LLLT on ocular surface modulation by correlating clinical outcomes with tear biomarker dynamics and developing predictive models to identify patients most likely to benefit from LLLT. Of the 98 patients initially randomized, 88 were included in the final analysis, with 44 allocated to the LLLT group and 44 to the sham treatment group. Clinical evaluation-including Ocular Surface Disease Index (OSDI) as the primary outcome, and tear breakup time, Schirmer test, and tear osmolarity as secondary endpoints-was performed preoperatively and one month postoperatively to classify patients as preclinical or having DED. Tear levels of biomarkers involved in tissue repair and neurotrophic-signaling (GDF-15,β-NGF, VEGFA, PDGF-AB, PDGF-CC) and inflammation (OPN, OPG, TNF-α) were assessed as exploratory endpoints and quantified using Luminex-FlexMap3D technology. LLLT-treated patients showed significantly higher clinical improvement post-cataract surgery than sham controls (44.2% vs. 4.4%; p < 0.0001). In DED patients, LLLT significantly increased GDF-15 (77.6 ± 7.2 to 95.5 ± 7.4 pg/mL; p = 0.0112) and PDGF-CC (711.4 ± 76.6 to 1024 ± 130.8 pg/mL; p = 0.0473). The LLLT-induced β-NGF increase was more pronounced in preclinical cases than in those with baseline DED (10.1 ± 3.02 vs. 5.8 ± 0.55 pg/mL; p = 0.0271). Biomarker profiles indicated inflammatory resolution post-LLLT, whereas sham-treated eyes showed persistent inflammation. Finally, integrative modeling of clinical and molecular data yielded a LASSO-adjusted AUC of 0.886, underscoring high discriminative performance. LLLT accelerates ocular surface recovery after cataract surgery by modulating reparative, neurotrophic, and inflammatory pathways. Tear biomarkers assessed at baseline and through one-month dynamics (GDF-15, PDGF-CC, β-NGF) and integrated with clinical parameters, may help predict treatment response and guide personalized postoperative management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.